WELL Health Technologies, a digital health company focused on tech-enabling healthcare providers, and its investee company, HEALWELL AI, are pleased to announce the launch of the second generation WELL AI Decision Support, (or ‘WAIDS’). This enhanced version which features advanced chronic disease screening arrives just six months after the initial launch, which was primarily focused on rare disease detection.
The upgraded WAIDS now includes screening capabilities for numerous chronic diseases such as chronic kidney disease, hypertension and diabetes, enabling risk stratification of patients into high, medium or low risk categories. This expansion broadens WAIDS’s utility in detecting more than one hundred rare and chronic diseases, providing clinically validated insights that identify care gaps and equip clinicians with actionable information at the point of care.
Dr Michael Frankel, Chief Medical Officer of WELL, said: “Adding chronic disease detection is a game-changer for our AI powered physician co-pilot tools. I have personally used this tool in my practice and found it to be of tremendous help and support. The tool compliantly scans my data and provides me with an overview of a number of key diseases as well as insights on which patients could be at higher risk or exposure to such diseases.”